Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
39.49
+2.12 (5.67%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 264 employees as of December 31, 2023. The number of employees increased by 68 or 34.69% compared to the previous year.
Employees
264
Change (1Y)
68
Growth (1Y)
34.69%
Revenue / Employee
$848,477
Profits / Employee
-$600,621
Market Cap
1.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264 | 68 | 34.69% |
Dec 31, 2022 | 196 | 59 | 43.07% |
Dec 31, 2021 | 137 | 69 | 101.47% |
Dec 31, 2020 | 68 | 35 | 106.06% |
Dec 31, 2019 | 33 | 9 | 37.50% |
Dec 31, 2018 | 24 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Warby Parker | 3,491 |
Zai Lab | 2,175 |
NeoGenomics | 2,100 |
Alignment Healthcare | 1,536 |
LeMaitre Vascular | 630 |
RxSight | 374 |
Verona Pharma | 79 |
MIRM News
- 11 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC - Business Wire
- 23 days ago - Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies - Benzinga
- 5 weeks ago - Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies - Business Wire
- 5 weeks ago - Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Business Wire
- 6 weeks ago - Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire